Zymeworks Inc. (ZYME)
Oxford Ledge is still expanding full research coverage of ZYME. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Zymeworks develops biotherapeutics for cancer and autoimmune diseases while building royalty streams through partnerships and acquisitions.
SEC filings
- 8-K Entry into material agreement; Regulation FD disclosure; Financial statements and exhibits 2026-06-29
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-05-14
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- 8-K Results of operations / financial condition; Regulation FD disclosure; Financial statements and exhibits 2026-05-07
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2026-04-01
Source: SEC EDGAR.
Annual results
5 years of annual figures for ZYME, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $106.0M | -$81.1M | -$1.08 |
| 2024 | $76.3M | -$122.7M | -$1.62 |
| 2023 | $76.0M | -$118.7M | -$1.72 |
| 2022 | $412.5M | $124.3M | $1.90 |
| 2021 | $26.7M | -$211.8M | -$4.61 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for ZYME. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ZYME in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.